In recent trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.42 million shares changing hands at last check today with its beta currently measuring 2.91. Company’s recent per share price level of $0.27 trading at -$0.04 or -10.98% at last check today assigns it a market valuation of $69.49M. That most recent trading price of ADAP’s stock is at a discount of -448.15% from its 52-week high price of $1.48 and is indicating a premium of 25.93% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.86 million shares which gives us an average trading volume of 1.69 million if we extend that period to 3-months.

For Adaptimmune Therapeutics Plc ADR (ADAP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.17 in the current quarter.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information

Upright in the red during last session for losing -10.98%, in the last five days ADAP remained trading in the green while hitting it’s week-highest on Wednesday, 04/02/25 when the stock touched $0.27 price level, adding 16.25% to its value on the day. Adaptimmune Therapeutics Plc ADR’s shares saw a change of -49.60% in year-to-date performance and have moved 23.41% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of -46.40% in past 30-days. Number of shares sold short was 5.64 million shares which calculate 4.59 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 91.0% to its recent value today. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -270.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -270.37% for stock’s current value.

Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts

This year revenue growth is estimated to fall -76.38% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.97M for the same. And 7 analysts are in estimates of company making revenue of 9.62M in the next quarter. Company posted 5.68M and 128.23M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 26.53% during past 5 years.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders

Insiders are in possession of 0.31% of company’s total shares while institution are holding 49.59 percent of that, with stock having share float percentage of 49.74%. Investors also watch the number of corporate investors in a company very closely, which is 49.59% institutions for Adaptimmune Therapeutics Plc ADR that are currently holding shares of the company. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ADAP for having 38.97 million shares of worth $38.0 million. And as of 2024-06-30, it was holding 2.5415 of the company’s outstanding shares.

The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 27.4 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.787 of outstanding shares, having a total worth of $26.72 million.

On the other hand, SPDR INDEX SHARES FUNDS-SPDR(R) Portfolio Developed World ex-US ETF and SEI INSTITUTIONAL INTERNATIONAL TRUST-SIT INTERNATIONAL EQUITY FUND are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025, the former fund manager was holding 272.49 shares of worth $73219.0 or 0.11% of the total outstanding shares. The later fund manager was in possession of 246.74 shares on Feb 28, 2025, making its stake of worth around $66300.0 in the company or a holder of 0.10% of company’s stock.